MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, MTNB had -$1,090K decrease in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
-$1,090K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-1,532 -6,901
Depreciation and amortization
-1 30
Gain on sale of assets
0 110
Stock based compensation expense
253 553
Change in operating lease right-of-use assets
111 218
Amortization of bond discount
-0
Change in finance lease right-of-use assets
1 2
Change in fair value of warrant liability
0 3,161
Operating lease liabilities
-195 -363
Prepaid expenses and other current assets
-205 -319
Accounts payable
-86 71
Accrued expenses and other liabilities
-230 -1,008
Net cash used in operating activities
-1,474 -4,028
Proceeds from maturities of marketable debt securities
-0
Purchase of marketable debt securities
-0
Proceeds from sale of assets
320 -
Net cash provided by investing activities
320 0
Gross proceeds from private placement of preferred stock and common stock warrants
0 3,300
Net proceeds from public offering of common stock and warrants
-0
Transaction costs paid pursuant to private placement
0 29
Net proceeds from exercise of warrants
64 -
Payments of finance lease liability principal
0 2
Net cash provided by financing activities
64 3,269
Net (decrease)/increase in cash, cash equivalents and restricted cash
-1,090 -759
Cash and cash equivalents at beginning of period
7,534 -
Cash and cash equivalents at end of period
5,685 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Matinas BioPharma Holdings, Inc. (MTNB)

Matinas BioPharma Holdings, Inc. (MTNB)